Literature DB >> 30737203

Novel Assay for Quantitative Analysis of DNA Methylation at Single-Base Resolution.

Huichuan Yu1, Liangliang Bai1, Guannan Tang1, Xiaolin Wang1, Meijin Huang2, Guangwen Cao3, Jianping Wang1,2, Yanxin Luo4,2.   

Abstract

BACKGROUND: The DNA methylation profile provides valuable biological information with potential clinical utility. Several methods, such as quantitative methylation-specific PCR (qMSP), have been developed to examine methylation of specific CpG sites. Existing qMSP-based techniques fail to examine the genomic methylation at a single-base resolution, particularly for loci in gene bodies or extensive CpG open seas lacking flanking CpGs. Therefore, we established a novel assay for quantitative analysis of single-base methylation.
METHODS: To achieve a robust single-base specificity, we developed a PCR-based method using paired probes following bisulfite treatment. The 6-carboxyfluorescein- and 2'-chloro-7'phenyl-1,4-dichloro-6-carboxy-fluorescein-labeled probes conjugated with minor groove binder were designed to specifically bind to the methylated and unmethylated allele of targeted single CpGs at their 3' half regions, respectively. The methylation percentage was calculated by values of methylation / (methylation + unmethylation).
RESULTS: In the detection of single CpGs within promoters or bodies of 4 human genes, the quantitative analysis of the single-base methylation assay showed a detection capability in the 1 to 1:10000 dilution experiments with linearity over 4 orders of magnitude (R 2 = 0.989-0.994; all P < 0.001). In a cohort of 10 colorectal cancer samples, the assay showed a comparable detection performance with bisulfite pyrosequencing (R 2 = 0.875-0.990; all P < 0.001), which was better than conventional qMSP methods normalized by input control reaction (R 2 = 0.841 vs 0.769; P = 0.002 vs 0.009).
CONCLUSIONS: This assay is highly specific and sensitive for determining single-base methylation and, thus, is potentially useful for methylation-based panels in diagnostic and prognostic applications.
© 2019 American Association for Clinical Chemistry.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30737203     DOI: 10.1373/clinchem.2018.298570

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  5 in total

1.  DNA methylation-based signature of CD8+ tumor-infiltrating lymphocytes enables evaluation of immune response and prognosis in colorectal cancer.

Authors:  Qi Zou; Xiaolin Wang; Donglin Ren; Huichuan Yu; Yanxin Luo; Bang Hu; Guannan Tang; Yu Zhang; Meijin Huang; Rish K Pai; Daniel D Buchanan; Aung Ko Win; Polly A Newcomb; William M Grady
Journal:  J Immunother Cancer       Date:  2021-09       Impact factor: 12.469

2.  Nomograms for Prediction of Molecular Phenotypes in Colorectal Cancer.

Authors:  Zhuojun Yu; Huichuan Yu; Qi Zou; Zenghong Huang; Xiaolin Wang; Guannan Tang; Liangliang Bai; Chuanhai Zhou; Zhuokai Zhuang; Yumo Xie; Heng Wang; Gaopo Xu; Zijian Chen; Xinhui Fu; Meijin Huang; Yanxin Luo
Journal:  Onco Targets Ther       Date:  2020-01-13       Impact factor: 4.147

3.  Genome-wide analysis identifies critical DNA methylations within NTRKs genes in colorectal cancer.

Authors:  Zijian Chen; Zenghong Huang; Yanxin Luo; Qi Zou; Liangliang Bai; Guannan Tang; Xiaolin Wang; Guangwen Cao; Meijin Huang; Jun Xiang; Huichuan Yu
Journal:  J Transl Med       Date:  2021-02-16       Impact factor: 5.531

4.  Methylation statuses of NCOR2, PARK2, and ZSCAN12 signify densities of tumor-infiltrating lymphocytes in gastric carcinoma.

Authors:  Xianyu Wen; Hye-Yeong Jin; Meihui Li; Younghoon Kim; Nam-Yun Cho; Yoonjin Kwak; Jeong Mo Bae; Hye Seung Lee; Gyeong Hoon Kang
Journal:  Sci Rep       Date:  2022-01-17       Impact factor: 4.379

5.  Accelerated biological aging in COVID-19 patients.

Authors:  Xue Cao; Wenjuan Li; Ting Wang; Dongzhi Ran; Veronica Davalos; Laura Planas-Serra; Aurora Pujol; Manel Esteller; Xiaolin Wang; Huichuan Yu
Journal:  Nat Commun       Date:  2022-04-19       Impact factor: 17.694

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.